RxDoctor Payments Data

Ju Kim

Family · Fayetteville, NYNPI 1710764550

Payments from drug & device makers

$1,622in general payments, 2019–2025

Across 74 payments — averaging $21.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$354
  • Boehringer Ingelheim$345
  • AstraZeneca$207
  • Merck$155
  • Amgen$135
  • Bayer$96
  • plus $330 from 9 others

What the payments were for

  • Food & beverage$1,622100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,622 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$18,979
Medicare patients
163
Services billed
366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban40$57,558
JardianceEmpagliflozin28$46,424
EntrestoSacubitril/Valsartan33$41,522
XareltoRivaroxaban19$26,724
Repatha SureclickEvolocumab22$24,638
Metoprolol Succinate109$1,485
Atorvastatin Calcium83$905
Rosuvastatin Calcium68$796
Ezetimibe46$727
Losartan Potassium47$609
Amlodipine Besylate105$533
Lisinopril51$420
ClopidogrelClopidogrel Bisulfate54$359
Metoprolol Tartrate57$301
Digoxin15$281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$57,55840 claims
Boehringer IngelheimJardiance$345$46,42428 claims
NovartisEntresto$354$41,52233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.

Other family in Fayetteville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →